Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs QR 010 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors ProQR Therapeutics
- 16 Aug 2017 Preliminary data from single ascending dose cohort of this study were presented at the European Cystic Fibrosis Conference, According to a ProQR Therapeutics media release.
- 15 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 15 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.